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Abstract
Pancreatic cancer remains a lethal disease. Although there are many reports on the survival rates of pancreatic cancer patients
after surgical resection, the clinicopathological characteristics that influence long-term survival over 5 years remain contro-
versial. Here, we clarify the favourable prognostic factors for long-term survival. One hundred and eighty-two patients with
pancreatic cancer underwent surgical resections from 1981 to 1997 in our department. Among them, eight patients survived
for at least 5 years after the surgery. The clinicopathological characteristics of the eight long-term survivors who underwent
radical resections were studied retrospectively. R0 surgical resections, including five combined with portal vein resections
(62.5%), were achieved in these eight patients. Negative invasions of the major regional artery (seven of eight, 87.5%) and to
the extrapancreatic nerve plexus (seven of eight, 87.5%), and N0 or N1 lymph node metastasis (7 of 8, 87.5%) were detected
as clinicopathological features of long-term survivors in our study. No exposure of carcinoma at the dissected surface and cut
end (seven of eight, 87.5%) was characteristically confirmed by pathology. Portal vein invasion was seen in three of the eight
patients (37.5%). For long-term survival in cases of pancreatic cancer, complete R0 resections should be performed and
negative invasions in the major regional arteries and to the extrapancreatic plexus of the nerve were necessary. No invasion to
the portal vein was not necessarily required if R0 was achieved by combined resection of the portal vein.
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Introduction
Today, pancreatic cancer remains a highly lethal
disease, and not many patients are able to live for
more than 5 years after pancreatic resection. Recently,
new technologies (computed tomography, ultra-
sonography, digital subtraction angiography, etc.) have
enabled us to detect the degree of tumour invasions
more accurately and to determine operability more
easily [1–3]. In addition, recent improvements in
surgical technologies have enabled us to better perform
extended radical resections in selected cases. However,
there are some scientists who maintain that the surgery
is not beneficial to patients in the advanced stage of
disease [4]. In our department, we have successfully
and safely performed pancreatectomies combined with
portal vein resections using antithrombogenic cathe-
ters for bypasses of the portal veins [5,6]. Apparent
superior mesenteric arterial invasions and/or complete
encasements of the portal vein were not detected
during resections in the portal veins [7].
Many authors have reported prognostic factors that
affect the long-term survival of pancreatic cancer
patients based on macroscopic and histological
findings and surgical factors [8–30]. However, most of
these authors regarded 3-year survivors as long-term
survivors because the prognosis of pancreatic cancer is
usually very poor. In actuality, many patients who live
for over 3 years after surgery still have recurrent
disease.
The aim of this study was to clarify the favourable
prognostic factors for long-term survival after curative
resection by studying the clinical data of several
patients who have survived after surgery for over 5
years, and investigating the criteria for patient selection
for radical surgery. The clinicopathological factors of
long-term survivors were thoroughly evaluated, and
the important factors contributing to long-term sur-
vival were also investigated.
Methods
Patients
One hundred and eighty-two patients with pancreatic
cancer underwent surgical resections in our depart-
ment from 1981 to 1997. All the patients’ medical
records were retrospectively reviewed. After excluding
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the patients with intraductal papillary mucinous
neoplasms (IPMNs), the long-term survivors who lived
for45 years after the surgery were studied on the bases
of surgical factors and clinicopathological findings.
These were used to identify the factors that seemed to
contribute to their long-term survival.
Surgical factors
Following the general rules of the Japan Pancreas
Society [30], the tumour location; tumour size (TS);
invasion to adjacent structures, e.g. common bile duct
(CH); duodenum (DU); pancreatic serosa (S); retro-
peritoneum (RP); portal vein (PV); major regional
artery, including the common hepatic artery, the
superior mesenteric artery, the splenic artery, and the
coeliac artery (A); and extrapancreatic nerve plexus
(PL) were all examined. Tumour nodal metastasis
(TNM) staging is determined by operative findings.
The T factor is defined as follows: T1, tumour size 2
cm and the tumour is limited to the pancreas; T2,
tumour size 42 cm and the tumour is limited to the
pancreas; T3, tumour is extended into CH, DU, S, or
RP; and T4, the tumour is extended into PV, A, PL, or
other organs. As for the severity of lymph node
metastasis, N0 indicates no nodal metastasis, N1
indicates positive metastasis in the region of the
tumour, N2 indicates positive metastasis in an exten-
sive region around the N1 region, and the positive N3
node means systemic disease and is equal to M1. The
degree of radicality, including the combined resection
of adjacent structures, was also studied.
Pathological factors
Microscopic findings, such as the histological grade,
invasion of the lymphatic duct (LY) and vessels (V),
and perineural invasion (NE) were studied. In order to
compare them with the operative findings, we also
pathologically examined the nodal status and local
invasions of adjacent structures, followed by the bile
duct (CH), duodenum (DU), pancreatic serosa (S),
retroperitoneum (RP), portal vein (PV), major regional
artery (A), and plexus of the nerve (PL). These were
studied together with the exposure of carcinoma on the
pancreatic cut end margin (PCM), the cut edge of the
bile duct (BCM), and the dissected peripancreatic
tissue margin (DPM). The term LY0 is used to indi-
cate that no invasion was microscopically detected in
the lymphatic duct around the tumour; LY1 indicates
mild invasion, LY2 indicates moderate invasion, and
LY3 indicates severe invasion. The factors V and NE
are also classified by the degree of invasion from V0 to
V3 and from NE0 to NE3, respectively, like the factor
LY. Final TNM staging and curability were deter-
mined by all of the pathological findings following the
general rules for the study of pancreatic cancer, which
were set by the Japan Pancreas Society [30].
Adjuvant therapy
In this study, we confirmed whether or not some
adjuvant therapies, such as intraoperative radiotherapy
(IORT) of 30 Gy using a linear accelerator (Linac)
and/or intraportal administration of 5-fluorouracil
(5-FU), were used.
Results
Twelve of the 182 pancreatic cancer patients (6.6%)
survived for 45 years after surgical resection. There
were 4 IPMN patients among the 12, and they were
excluded from our study. The characteristics of the
remaining eight patients with invasive pancreatic
cancer are shown in Table I.
There were six males and two females among the
eight patients, and their mean age was 58.3 years at the
time of operation (range 46–68); their mean survival
period was 6.4 years after the surgery (range 5–9.5).
Three of the eight patients survived without recurrence
into the year 2002, three died from the recurrent
disease, and two succumbed to another disease.
Tumour sites were located on the pancreatic head in
seven cases, and in the body in one case. Among the
eight patients, one underwent a distal pancreatectomy,
four received pancreatoduodenectomies (PD), and
three had pylorus-preserving pancreatoduodenec-
tomies (PPPD). Five pancreatic head cancer patients
underwent combined resections of the PV, which were
successfully performed without residual cancer. All
eight patients underwent regional lymph node dissec-
tions that included the para-aortic region.
We performed radical resections including wide
dissections of the regional lymph nodes, retro-
peritoneal tissues and extrapancreatic nerve plexuses
for those with advanced pancreatic cancer. All eight
patients macroscopically underwent en bloc resections
without cancer exposure at the sites of the cut ends and
dissected edges. The pancreatic cut end margin (PCM
factor), bile duct cut end margin (BCM factor), and
dissected peripancreatic tissue margin (DPM factor)
Table I. Characteristics of patients.
Patient
no.
Age/
sex
Survival
period
(years) Outcome
Tumour
site
Adjuvant
therapy Operation
1 64/M 9.5 Dead Head None PD
2 68/F 8 Dead Body IR+FU PD
3 46/M 5 Dead Head,
body
None PD
4 62/M 8.9 Dead Head FU PD
5 54/M 5 Dead Head IR+FU PPPD
6 62/M 5.3 Alive Head IR+FU PPPD
7 51/F 5 Alive Head None PPPD
8 60/M 5 Alive Head IR+FU PD
M, male; F, female; None, adjuvant therapy not given; PD,
pancreatoduodenectomy; PPPD, pylorus-preserving pancreatoduo-
denectomy; IR, irradiation; FU, 5-fluorouracil administration.
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were found to be macroscopically negative for all eight
patients and were microscopically proven as cancer-
negative for seven of eight patients.
The operative findings are listed in Table II. The
tumour size (TS) factors are classified into four
degrees. TS1 means a tumour size within 2.0 cm, TS2
means that it is between 2.0 cm and 4.0 cm, TS3
means that it is between 4.0 cm and 6.0 cm, and TS4
means that it is larger than 6.0 cm. These eight patients
were macroscopically classified as follows: TS1, 25%;
TS2, 50%; TS3, 25%; and TS4, 0%.
Five patients (62.5%) were observed with invasion
to the intrapancreatic bile duct (positive CH factor),
three (37.5%) with invasion to the duodenum (positive
DU factor), four (50%) with invasion to the pancreatic
serosa (positive S factor), four (50%) with invasion to
the retroperitoneum (positive RP factor), five (62.5%)
with invasion to the portal vein (positive PV factor),
and one (12.5%) with invasion to a major regional
artery at the splenic artery, as well as the extra-
pancreatic nerve plexus (positive PL factor). The
severity of lymph node metastases in the eight cases
was: N0, five cases (62.5%); N1, two cases (25%); and
N2, one case (12.5%).
The surgical T factors of TNM classification were
found as follows: T1, no cases (0%); T2, no cases
(0%); T3, four cases (50%); and T4, four cases (50%).
The surgical stages of the eight patients were: stage I,
no cases (0%); II, no cases (0%); III, four cases (50%);
and IV, four cases (50%). All five patients with
suspected PV invasion underwent combined resections
of the PV. PCM, BCM, and DPM were concluded to
be surgically negative in all eight cases (100%).
The pathological findings are shown in Table III.
Invasive cancer was detected in all eight cases (100%).
The histological types of the tumours were as follows:
well differentiated tubular carcinoma was detected in
one case (12.5%), moderately differentiated tubular
adenocarcinoma in six cases (75%), and mucinous
carcinoma in one case (12.5%). The pathological
factors of the DU, A, PL, BCM and PCM were
consistent with the macroscopic findings. The CH,
PV, S and RP factors were not consistent with the
surgical diagnoses in one case (no. 7), two cases (nos 4
and. 8), two cases (nos 2 and 8) and two cases (nos 1
and 8), respectively. The DPM was also not consistent
with the macroscopic diagnosis in one case (no. 5). The
factors of LY and NE were confirmed as follows: LY0,
Table II. Surgical factors.
Patient
no. TS CH DU S RP PV A PL T N
JPS
stage
UICC
stage
PCM
BCM
DPM
Combined
resection
1 2 7 7 7 + 7 7 7 3 1 III III – –
2 2 7 7 + 7 7 7 7 3 0 III II – –
3 3 + + + + + 7 7 4 2 IVb 1V A – Portal vein
4 2 + + + + + 7 7 4 0 IVa IV A – Portal vein
5 2 + 7 7 + + + + 4 0 IVa IV A – Portal vein
6 1 + 7 7 7 + 7 7 3 0 III II – Portal vein
7 1 + 7 7 7 7 7 7 3 0 III II – –
8 3 7 + + + + 7 7 4 1 IVa IV A – Portal vein
CH, choleduct; DU, duodenum; S, serosa; RP, retroperitoneum; PV, portal vein; A, major regional artery; PL, peripancreatic nerve plexus;
PCM, pancreatic cut end margin; BCM, bile duct end margin; DPM, dissected peripancreatic tissue margin. The JPS stage is the TNM stage
determined by the Japan Pancreas Society. The UICC stage is the TNM stage determined by UICC.
Table III. Pathological findings.
Patient
no. Histology CH DU S RP PV A PL pT pN
JPS
f-stage
UICC
f-stage LY V NE
PCM
BCM
DCM pR
1 Muc 7 7 7 + 7 7 7 3 1 III III 2 0 0 7 0
2 Tub mod 7 7 7 7 7 7 7 1 0 I I 1 1 2 7 0
3 Tub mod + + + + + 7 7 4 2 IVb IV A 3 1 2 7 0
4 Tub mod + + + + + 7 7 4 0 IVa IV A 1 1 1 7 0
5 Tub mod + 7 7 + + + + 4 0 IVa IV A 1 0 3 + 1
6 Tub mod + 7 7 7 7 7 7 3 0 III II 1 0 1 7 0
7 Tub well 7 7 7 7 7 7 7 1 0 I I 0 0 3 7 0
8 Tub mod 7 + 7 7 7 7 7 3 1 III III 1 1 1 7 0
Muc, mucinous carcinoma; Tub mod, tubular adenocarcinoma, moderately differentiated type; Tub well, tubular adenocarcinoma, well
differentiated type; CH, choleduct; DU, duodenum; S, serosa; RP, retroperitoneum; PV, portal vein; A, major regional artery; PL, peri-
pancreatic nerve plexus; PCM, pancreatic cut end margin; BCM, bile duct end margin; DPM, dissected peripancreatic tissue margin; R,
residual tumour; P, pathological diagnosis; F, final diagnosis. The JPS f-stage is the final confirmed TNM stage determined by the Japan
Pancreas Society. The UICC f-stage is the TNM stage determined by UICC.
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12.5%; LY1, 62.5%; LY2, 12.5%; LY3, 12.5%; NE0
12.5%; NE1, 37.5%; NE2, 25%; and NE3, 25%.
Regarding the V factor, all cases were distinctively
categorized within V0 (50%) and V1 (50%), whereas
V2 and V3 were both 0%. The final confirmed T
factors were: T1 in two cases (25%), T2 in no cases
(0%), T3 in three cases (37.5%), and T4 in three cases
(37.5%). Final staging confirmed by the pathological
findings was as follows: stage I, two cases (25%); II, no
cases (0%); III, three cases (37.5%); and IV, three
cases (37.5%).
Adjuvant therapy of intraportal 5-FU infusion was
given in one case (no. 4). Combined therapies
consisting of intraoperative irradiation using Linac and
intraportal 5-FU infusion chemotherapy were per-
formed in the four cases (nos 2, 5, 6 and 8) who under-
went radical resection. R0 was achieved in all five cases.
Discussion
Many authors have used the statistical analysis method
to discuss the prognostic factors that influenced long-
term survival after surgical resection for pancreatic
cancer [8–30]. They presented us with several
beneficial factors, as follows: radical resection en bloc
without residual cancer [12,16], a smaller tumour size
[13,17,25], an operator or institutional factor [19], a
histological differentiation [25,26], no frontal invasion
of the pancreatic capsule, no retroperitoneal invasion
[27], negative resection margins [27–29], a negative
lymph node, a positive lymph node within the limited
nodal status [8–10,17,18,22–25,27,30], negative
invasion of blood vessels [24], negative perineural
invasion [8,11,22], and the tumour location [12,17].
However, most authors regarded patients who survived
for 43 years as long-term survivors, and only a few
studied and evaluated these prognostic factors in
patients who survived for45 years.
Based on our study, four of these factors were
considered important for long-term survival. They are:
1) resection without residual cancer; 2) no lymph node
metastasis, or if present, limited within the N1 level; 3)
no invasion of major regional arteries, including the
superior mesenteric artery, common hepatic artery,
splenic artery, and coeliac artery; and 4) no invasion of
the extrapancreatic nerve plexus. As for the portal vein,
Nakao et al. reported that if it is invaded, and if R0
resection is completed by portal vein resection, the
survival rate is still more favourable than in the case of
negative portal invasion with positive margin invasion
[28]. In the eight patients that we studied, portal
invasion was histologically confirmed in three (37.5%),
and the percentage was surprisingly high.
There is no validity in the argument that the true
curative resection is the R0 resection, and that R0
resection is identified as a valuable factor for long-term
survival [28]. To achieve R0 resection, we usually
perform a radical resection with the dissection of the
regional lymph node and the retropancreatic tissue,
including the extrapancreatic nerve plexus for invasive
pancreatic cancer. For intraoperative diagnosis of the
portal vein and PL invasion, intraportal endovascular
ultrasonography (IPEUS) is helpful [2,32]. Portal vein
resection is important in obtaining a carcinoma-free
surgical margin in pancreatic cancer surgery [7]. If
such a surgical margin cannot be obtained by extensive
surgery, there is no indication for surgical resection in
patients with pancreatic carcinoma.
Authors of some reports have claimed that stage III
pancreatic cancer defined by the UICC rules should
not be resected if neoadjuvant therapy is not effective
[4]. However, we do not agree with this opinion,
because in our study, five of the eight cases were clas-
sified as stages III or IV according to the UICC rules.
The difference of these two opinions may be because of
the difference in the extent of resection that could be
performed safely.
If the extent of lymph node dissection is insufficient,
we may misdiagnose cancer invasion. Therefore, it is
not easy to predict long-term survival by TNM staging
alone. Furthermore, as demonstrated in this study, a
diagnostic discrepancy between macroscopic and
microscopic findings may occur, so it is important to
investigate the resected specimen carefully to correctly
determine the final staging and whether or not R0
resection has been achieved. As the advanced stage in
TNM classification was seen in most of our eight long-
term survivors, consideration of those surgical and
pathological factors, as well as TNM staging, is
necessary to understand the tumour characteristics and
to predict the prognosis. In general, there are many
local factors as regards how the cancer invades around
the pancreas. From the surgical standpoint, A0, PL(–),
and R0 (DPM, PCM, BCM) were important factors
affecting long-term survival. Furthermore, it was
suggested that portal vein invasion does not exclude
operative indication. T3 and T4 of the TNM classifi-
cation were identified in 100% of the eight patients on
surgical findings and 75% on pathology.
In the inconsistency between surgical and patholo-
gical diagnoses, a discrepancy seen in the CH factor in
one case (no. 7) might be because of the existence of
pancreatitis around the tumour. In five of the eight
patients who underwent portal vein resections, portal
invasion was pathologically positive only in three cases
(nos 3, 4 and 5). This may have been caused by
misdiagnosis due to compression of the portal vein,
possibly because of a large tumour or accompanying
pancreatitis. IPEUS can accurately differentiate
between compression and a subtle portal venous
invasion and reduce this discrepancy [3]. However,
portal vein resection was considered to be necessary to
obtain cancer-free margins in those cases.
Some authors have explained the benefits of using
adjuvant therapies, including chemotherapy and radio-
therapy [18,34,35]. As already shown, we also consider
radiotherapy to be an effective method to control the
pain caused by the infiltration of carcinoma into the
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extrapancreatic nerve plexus [36,37]. However, irra-
diation does not improve the prognosis. We employed
intraoperative combined adjuvant therapies consisting
of radiation and 5-FU chemotherapy in four of the
eight patients. However, the true feasibility of adjuvant
therapy for long-term survival was not clarified in this
study. Protocols evaluating the efficacy of Gemcitabine
(difluorodeoxycytidine; dFdC), a new chemother-
apeutic agent for pancreatic cancer, are now underway
in randomized controlled trials.
From this study, we conclude that in order to achieve
a long-term survival goal, it is important to perform a
complete R0 resection. When portal vein invasion is
suspected without invasion to the major regional
arteries and distant metastasis at the time of operation,
a pancreatectomy with combined resection of the portal
vein is to be performed to achieve a curative resection.
Moreover, if PL(7), DPM, PCM and BCM(7) are
microscopically confirmed in the resected specimen, a
favourable outcome can be expected after the surgery.
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